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Abstract
Introduction: Stress has been shown to be a tumor promoting factor. Both clinical and laboratory studies have
shown that chronic stress is associated with tumor growth in several types of cancer. Corticotropin Releasing
Factor (CRF) is the major hypothalamic mediator of stress, but is also expressed in peripheral tissues. Earlier studies
have shown that peripheral CRF affects breast cancer cell proliferation and motility. The aim of the present study
was to assess the significance of peripheral CRF on tumor growth as a mediator of the response to stress in vivo.
Methods: For this purpose we used the 4T1 breast cancer cell line in cell culture and in vivo. Cells were treated
with CRF in culture and gene specific arrays were performed to identify genes directly affected by CRF and
involved in breast cancer cell growth. To assess the impact of peripheral CRF as a stress mediator in tumor growth,
Balb/c mice were orthotopically injected with 4T1 cells in the mammary fat pad to induce breast tumors. Mice
were subjected to repetitive immobilization stress as a model of chronic stress. To inhibit the action of CRF, the
CRF antagonist antalarmin was injected intraperitoneally. Breast tissue samples were histologically analyzed and
assessed for neoangiogenesis.
Results: Array analysis revealed among other genes that CRF induced the expression of SMAD2 and b-catenin,
genes involved in breast cancer cell proliferation and cytoskeletal changes associated with metastasis. Cell
transfection and luciferase assays confirmed the role of CRF in WNT- b-catenin signaling. CRF induced 4T1 cell
proliferation and augmented the TGF-b action on proliferation confirming its impact on TGFb/SMAD2 signaling.
In addition, CRF promoted actin reorganization and cell migration, suggesting a direct tumor-promoting action.
Chronic stress augmented tumor growth in 4T1 breast tumor bearing mice and peripheral administration of the
CRF antagonist antalarmin suppressed this effect. Moreover, antalarmin suppressed neoangiogenesis in 4T1 tumors
in vivo.
Conclusion: This is the first report demonstrating that peripheral CRF, at least in part, mediates the tumor-
promoting effects of stress and implicates CRF in SMAD2 and b-catenin expression.
Corticotropin Releasing Hormone stress, 4T1, breast cancer
Background
Stress has been described as a promoter of tumor
growth and angiogenesis in different in vivo models [1].
Thus, it has been considered that during chronic stress
and depression, the persistent activation of the hypotha-
lamic-pituitary-adrenal (HPA) axis is probably responsi-
ble of an impaired immune response, contributing to
the development and progression of several types of
cancer [2].
Corticotropin Releasing Factor (CRF) was the first pep-
tide isolated from the now named CRF-related peptides
family that also includes urocortin 1, urocortin 2 and
urocortin 3. This family of peptides exerts its biological
actions through the activation of two receptors: CRF
receptor 1 (CRF1) and CRF receptor 2 (CRF2). CRF exert
its effect primarily via CRF receptor 1 and at a lesser
extent via CRF2 [3], exhibiting a 10 fold higher affinity
for the former.
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central nervous system, its primary site of expression,
but also in peripheral tissues and organs [3]. Indeed,
multiple studies have shown that CRF mediates endo-
crine responses to stress, not only by activating the
HPA axis but also via direct actions in the periphery
[4-6]. In this regard, the CRF-based paracrine activity
has been postulated to participate in the modulation of
stress effects on the gastrointestinal system [5]. More-
over, CRF-related peptides exert direct actions on cardi-
omyocytes mediating the adaptive response of the
cardiovascular system to stressful conditions such as
ischemia and reperfusion [7,8].
In the tumor microenvironment, CRF is released by
endothelial and immune cells and by the local neuronal
innervation [9-11]. Moreover, peptides of the CRF family
and their receptors have been also found expressed by
several cancer cells [12], such as human renal cell carci-
noma [13], tumorous adrenocortical cells [14], human
endometrial, prostate, ovarian and breast cancer cells
[14-19], human pheochromocytoma cells and melanomas
[20-22] and the murine melanoma cell line B16F10 [23].
However, the effects exerted by CRF in cancer cells range
from promotion of cancer cell proliferation and migra-
tion to inhibition of proliferation and induction of angio-
genesis. Thus, CRF has been described to inhibit cell
proliferation via CRF1 in the endometrial adenocarci-
noma cell line Ishikawa [24] and in the human HaCaT
keratinocytes [25]. In contrast, in the Y79 retinoblastoma
cell line CRF suppresses apoptosis via downregulation of
pro-caspase 3 cleavage and activation [26] and in the
B16F10 murine melanoma cell line it enhances cell
migration through the ERK1/2 pathway [23]. Moreover,
in the human breast cancer MCF7 cells, an estrogen-
dependent tumor cell line, CRF inhibits cell proliferation
but promotes motility and invasiveness via the activation
of CRF1 [17,18]. In addition, CRF induces local immuno-
suppression by promoting apoptosis of cytotoxic T-cell
via the prduction of Fas ligand (FasL) in ovarian cancer
cells [19].
The aim of the present study was to test the role of
peripheral CRF as a mediator of stress response on
breast cancer cell growth using both in vivo and in vitro
studies on the 4T1 breast cancer cell line. In the first
part of this work we evaluated the direct effects of CRF
on this cell line in culture. In the second part, we used
a mouse model of orthotropic injection of breast cancer
cells in the mammary fat pad of Balb/c mice. In this
model we studied the effect of stress on tumor growth
and we evaluated the impact of inhibition of peripheral
CRF. For this purpose we administered antalarmin intra-
peritoneally, which does not affect stress-induced
Hypothalamus-pituitary-adrenal (HPA) axis responses
[27]. In this way, we determined the effect of peripheral
CRF inhibition on tumor growth in the presence or
absence of stress exposure.
Our results showed that CRF increased proliferation,
migration and actin polymerization in 4T1 cells. More-
over, it modified the expression of several molecules
involved in tumor growth and metastasis. Two of them,
SMAD2 and b-Catenin, transcription factors connected
with the TGFb and the Wnt signaling pathways respec-
tively [28,29], were increased following CRF treatment.
Finally, in vivo studies demonstrated that peripheral
CRF induced angiogenesis and tumor growth in vivo.
Results
1. Expression of CRF receptors in 4T1 cells
The expression of CRF receptors in 4T1 cells has not
been previously reported. To asses any possible direct
effect of CRF in 4T1 cells, our first aim was to investi-
gate the expression of CRF receptor 1 and 2 in this cell
line. Our results confirmed that 4T1 cells expressed
high levels of CRF1 receptor and very low levels of CRF2
receptor type b (CRF2b)( Figure 1). Similarly, previous
studies from our group had shown that MCF7 breast
cancer cells also express CRF1 receptor and low levels of
CRF2 [18].
2. CRF induces proliferation of 4T1 cells in a time-
dependent manner
Regulation of cancer cell proliferation is readily associated
with malignancy. CRF has been previously described to
reduce proliferation of cancer cell lines such as Ishikawa
endometrial carcinoma cells, pheochromocytoma cell lines
Figure 1 Expression of CRF receptors in 4T1 cells. CRF receptor
1 and low levels of CRF receptor 2 were found expressed in 4T1
cells.- Con, negative control (non rt); + Con, positive control (mouse
brain).
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Page 2 of 13and the breast cancer cell line MCF7 [17,18,20,21,24]. In
the Y79 retinoblastoma cell line, however, CRF suppresses
apoptosis [26]. To asses the effect of CRF on 4T1 cell pro-
liferation, 4T1 cells were treated with different doses of
CRF for different time points. The results indicated that
CRF promoted 4T1 cell proliferation with the most effec-
tive dose being 10
-9 M being evident at 48, 72 and 96
hours (Figure 2). No effect on proliferation was observed
at 24 hours. To determine if this effect was abrogated by
the CRF1 antagonist Antalarmin, we treated cells with dif-
ferent concentrations of CRF for in the presence or
a b s e n c eo fA n t a l a r m i nf o rt h es a m et i m ep e r i o d s .T h e
results indicated that CRF promoted 4T1 proliferation via
CRF1 receptor (Figure 2).
3. CRF affects the expression of molecules involved in
tumor cell growth and metastasis: induction of b-catenin
and SMAD2 in a time-dependent manner
To further evaluate the effect of CRF in tumor cell
growth and metastasis in our system, RNA from 4T1
cells untreated and treated with 10
-8M CRF at the indi-
cated time points was analyzed using a gene-specific
oligo microarray for 113 genes known to be involved in
tumor growth and metastasis (Superarray, Qiagen).
Image data were transformed into numerical and into
color intensity data as described in Materials and
methods.
The ratio of gene expression in CRF-treated to
untreated cells was used to determine increased or
decreased RNA expression of genes after CRF treatment.
Our data showed that CRF modifies the expression of
several molecules involved in tumor cell growth and
metastasis that can be classified in groups according to
function as shown in Table 1. Figure 3 illustrates the
color intensity analysis according to the expression
levels of genes affected by CRF treatment.
Interestingly, our results with the oligo-microarrays
pointed out the CRF-induced expression of two essential
transcription factors involved in metastasis: b-catenin
and SMAD2. To confirm these results, western blot
were performed as described in Materials and methods.
The potential effect of CRF on b-catenin and subse-
quently Wnt signaling may confer a novel mechanism
for crosstalk between breast cancer cells and stress neu-
ropeptides. Our results with western blot confirmed that
CRF rapidly induced b-catenin expression at the protein
level (Figure 4A, B). Up-regulation of SMAD2, a down-
stream mediator of TGF-b signaling [28] was also con-
firmed by western blot analysis (Figure 4B, C).
To address the functional significance of the induction
of b-catenin in 4T1 cells, we transfected 4T1 cells with
a WNT reporter construct containing Tcf binding ele-
ments upstream the luciferase gene and treated them
with CRF. The results indicated that CRF treatment
augmented WNT signaling, confirming the functional
significance of b-catenin induction. The effect was abro-
gated when the Tcf binding consensus was mutated
(Figure 4D). To confirm the importance of CRF-induced
Smad2 expression, we assessed the effect of CRF on
TGFb signaling. 4T1 cells were treated with TGFb in
the presence or absence of CRF and cell proliferation
was measured. The results indicated that CRF augmen-
ted TGFb-induced proliferation of 4T1 cells (Figure 4E).
4. CRF increased actin polymerization in 4T1 cells
It has been reported that TGF-b and b-catenin are
involved in cell motility and invasiveness in epithelial
cancer cells and in cytoskeletal changes, respectively
[30]. Since our results showed that the expression of b-
catenin and SMAD2 is increased in 4T1 cells by CRF,
we therefore examined the impact of CRF on cytoskele-
tal changes in this cell line.
To this aim, 4T1 cells were treated with 2 × 10
-8M CRF
and stained with rhodamine-phalloidin, as described in
Materials and methods. The toxin phalloidin, conjugated
to the fluorescent dye rhodamine, binds specifically to
polymerized actin allowing us to visualize the architec-
ture of actin in the cell. Cells treated with CRF showed
Figure 2 Effects of CRF on 4T1 cells proliferation. 4T1 cells were treated with different doses of CRF for 48 to 96 hours. CRF significantly
induced proliferation of 4T1 cells, as measured by the MTT assay. The CRF1 antagonist Antalarmin reversed this effect. Data are expressed as the
MEAN ± SEM of three independent experiments. * p < 0.05 compared to untreated control cells, + p < 0.05 compared to cells treated with 10
-
8M CRF and # p < 0.05 compared to cells treated with 10
-9M CRF.
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Page 3 of 13more intense staining compared to the untreated
controls, most extensively seen after 4 h treatment
(Figure 5A). In addition, CRF treated cells showed
increased actin stress fibers (Figure 5B). The altered
actin structures seen after CRF treatment might be asso-
ciated with an increase in cancer cell motility, a process
necessary for tumor cells to invade and metastasize. To
assess the impact of CRF on 4T1 motility and migration
we performed the wound healing assay, in which a gap is
formed in a cell monolayer and the speed of cell migra-
tion was estimated by measuring the closure of the gap.
The results indicated that CRF promoted 4T1 cell moti-
lity and migration (Figure 6A) further supporting our
hypothesis. Antalarmin reversed the effect implicating
CRF1 receptor.
In order of tumors to grow and cancer cells to metas-
tasize neoangiogenesis is required. Earlier studies from
our group had shown that CRF induced Cox-2 expres-
sion [31], an enzyme known to promote angiogenesis
via production of prostaglandins [32]. Indeed, treatment
of 4T1 cells with CRF induced Cox-2 expression sug-
gesting a potential impact on metastasis (Figure 6B).
VEGF is a key factor that promotes angiogenesis. Treat-
ment of 4T1 cells with CRF did not result in detectable
VEGF expression (data not shown), suggesting that CRF
may utilize a Cox-2 dependent, VEGF-independent
mechanism to promote angiogenesis.
5. Evaluation of the in vivo model of chronic stress
In order to greater extent the molecular mediators of
CRF on tumor growth and the effect of peripheral CRF,
we used an in vivo model of restraint stress (see Materi-
als and methods) and antalarmin, a synthetic CRF1
receptor antagonist [33,34].
Firstly, to confirm that peripheral administration of
antalarmin does not affect the role of CRF in the
response of the HPA axis to stress, levels of corticoster-
one in serum were determined in the different groups of
mice immediately after the last exposure to stress. Thus,
corticosterone levels were significantly increased upon
stress and were not affected by antalarmin. This sug-
gests that when antalarmin is administered peripherally,
it does not affect corticosterone production triggered by
immobilization stress (Figure 7A).
Secondly, to determine whether our experimental
setup indeed resembled chronic stress, we measured
corticosterone on the 4
th day of the interval that fol-
lowed the last exposure to stress. In this manner, we
confirmed that the corticosterone levels in the plasma
were still increased, indicating that the mice were
exposed to chonic stress. In addition, we confirmed
again that antalarmin administrated intraperitoneally did
Table 1 List of genes affected by CRF
Functional groups GenBank Name Symbol Ratio
control/CRF 6 h
Ratio
control/CRF 24 h
1, 3, 5 NM 007614 b-Catenin Catnb 1.43* 1.00
2, 3 NM 008284 Harvey rat sarcoma virus oncogene 1 Hras1 1.00 1.41*
2, 4 NM 008960 Phosphatase and tensin homolog Pten 1.00 1.44*
2, 5 NM 009029 Retinoblastoma 1 Rb1 0.97 1.65*
3 NM 007484 Ras homolog gene family, member C Rhoc 1.01 1.42*
5 NM 010754 MAD homolog 2 Smad2 2.32* 0.98
6 NM 174991 Brain-specific angiogenesis inhibitor 1 Bai1 0.44* 0.57*
2, 3 NM 134155 Breast cancer metastasis-suppressor 1 Brms1 0.60* 0.85
2, 5 NM 009870 Cyclin-dependent kinase inhibitor 2A Cdkn2a 0.31* 0.59*
Functional groups: 1, Cell adhesion; 2, Cell cycle; 3, Cell growth and proliferation; 4, apoptosis; 5, Transcription factors and regulators; 6, Other genes involved in
metastasis. *, increase or decrease equal or higher than 40%.
Figure 3 Effects of CRF on the expression of molecules
involved in tumor growth and metastasis. Gene-specific oligo
microarrays for 113 genes known to be involved in tumor growth
and metastasis were performed as described in Materials and
methods. Effect of CRF on the expression of these molecules in 4T1
cells was analyzed. Mean expression of each gene was transformed
into color intensity using the program TIGR MultiExperiment Viewer
V4.5.1. The minimal value (green) and the maximum (red) were
considered the limits (as noticed in bar above). The figure shows
the molecules which expression was affected by CRF after 6 or 24 h
of treatment: Bai1, Brain-specific angiogenesis inhibitor 1; Brms1,
Breast cancer metastasis-suppressor 1; Ctnnb1, b-Catenin; Cdkn2a,
Cyclin-dependent kinase inhibitor 2A; Smad2, MAD homolog 2;
Hras1, Harvey rat sarcoma virus oncogene 1; Pten, Phosphatase and
tensin homolog; Rb1, Retinoblastoma 1; Rhoc, Ras homolog gene
family, member C.
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was observed between mice injected with vehicle or
antalarmin and exposed to stress (Figure 7B).
6. Peripheral CRF promoted tumor growth and induced
angiogenesis in vivo
As described in Materials and methods, six weeks after
the injection of 4T1 cells into the mammary fat pad of
mice, mammary glands were visualized on the animal to
determine the extent of neoangiogenesis and samples
were collected to perform histological analysis.
Histological and optical imaging analysis of the tumors
revealed that in mice not exposed to stress, administra-
tion of antalarmin resulted in reduced tumor burden.
Upon stress the percentage of tumor-bearing animals
was increased compared to non-stressed animals.
Administration of antalarmin in stressed animals
resulted in reduction of the percentage of tumor-bearing
mice (Figure 8A). No significant difference in tumor
size was observed. Histological analysis in the lung and
liver revealed no metastasis in the groups analyzed (data
not shown). Representative photographs of mammary
Figure 4 CRF induced the expression of b-catenin and SMAD2. Western blot analysis were performed as described in Materials and methods
in order to asses the effect of CRF on b-catenin and SMAD2 expression at protein levels. CRF significantly induced the expression of b-catenin
(A,B) at 4 and 6 h whereas the expression of SMAD2 (A, C) was significantly induced at 6, and 24 h. Data are expressed as MEAN ± SEM of five
independent experiments. * p < 0.05 compared to untreated control. D. 4T1 cells were transfected with a luciferase construct containing a WNT-
responsive element in which the complex of b-catenin and Tcf binds. Cells were stimulated with CRF and luciferase activity was measured in cell
lysates 24 hours following stimulation. Data are expressed as MEAN ± SEM of three independent experiments (*p < 0.05). E. 4T1 cells were
stimulated with TGFb at 5 ng/ml in the presence or absence of CRF at 10
-8M and proliferation was measured using the MTT assay. Data are
expressed as MEAN ± SEM of three independent experiments. * p < 0.05 compared to TGFb -only treated cells.
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Page 5 of 13tissues stained with Haematoxylin-Eosin are shown in
Figure 8B.
Angiogenesis is a hallmark of tumor growth and metas-
tasis. Recent studies have indicated that CRF affects
neoangiogenesis and that CRF1 mediates this effect [35].
We therefore evaluated the extent of neoangiogenesis in
the 4T1 tumors and the impact of stress and CRF inhibi-
tion. To quantitatively measure angiogenesis, we used an
image analysis approach based on the contrast of light
autofluorescence between the mammary tissue and the
blood vessels. Blood vessels absorb visible light, while
mammary gland and mammary tumors are strongly auto-
fluorescent. A user-friendly software was developed
in-house and used to quantify the relative area of blood
vessels in the tissue. The results showed that tumor-
bearing mammary glands had increased angiogenesis
compared to normal mammary glands and angiogenesis
was significantly increased when mice were exposed to
stress (Figure 8C). Treatment of mice exposed to stress
with antalarmin resulted in reduced angiogenesis. Our
results suggest that stress augments neoangiogenesis in
breast tumors and a potential mediator is peripheral
CRF, since treatment with antalarmin suppressed stress-
induced neoangiogenesis.
Discussion
The impact of stress on the development of cancer has
been widely proposed [1,2,36]. The stress response
involves the activation of cascades in both the central
and the peripheral nervous systems. CRF is the main
hypothalamic stress-induced neuropeptide and its per-
ipheral effect has also been reported in several systems
[3,5,8,9,31,37-39]. Thus, the objective of this work was
to analyze the role of peripheral CRF as a mediator of
stress effects on cancer cells in a murine model of breast
cancer. To this aim, we first analyzed the expression of
CRF receptors in 4T1 cells in order to assess any direct
effect of CRF on this system. In the present study we
found that 4T1 cells expressed high levels of CRF1
receptor and low levels of CRF2b receptor. The expres-
sion of CRF receptors have been described in other can-
cer cell lines. In fact, previous studies from our group
had shown that MCF7 breast cancer cells also express
CRF1 receptor and low levels of CRF2.H o w e v e r ,i nt h e
present work we found that in 4T1 cells CRF induced
cell proliferation, whereas in MCF7, and others cell lines
such as the adenocarcinoma cell line Ishikawa and the
human HaCaT keratinocytes [18,24,25], proliferation
was suppressed by CRF. In contrast, CRF induced prolif-
eration of the At20 corticotrophic adenocarcinoma cell
line and primary canine corticotrophic adenoma cells
[40,41]. This discrepancy is in accordance with previous
works describing that the phenotypic effects of CRF on
cell proliferation were dependent on both cell type and
nutrition conditions [42]. Therefore using non malig-
nant cells it has been shown that CRF stimulated dermal
fibroblasts proliferation while it inhibited cell prolifera-
tion in keratinocytes [42].
Since different reports support positive or negative
actions of CRF on cancer cell growth and metastasis we
assessed the effect of CRF on the expression pattern of
genes involved in cancer cell metastasis. For this purpose
we used gene-specific oligo microarrays. Our results
demonstrated that CRF treatment increased expression
of Smad2 and b-catenin, and suppressed the expression
of the angiogenesis inhibitor Bai1, the metastasis sup-
pressor Brms1 and the cell cycle regulator Cdkn2a/p16.
In addition, CRF also enhanced the expression of mole-
cules involved in cell cycle, proliferation and apoptosis,
such as Ha-ras1, Myb, Pten, Rb1 and RhoC. Our studies
focused on the impact of CRF on SMAD2 and b catenin,
being molecules involved in two central signaling path-
ways regulating breast cancer growth and metastasis,
these of TGFb and Wnt respectively [28,29].
Figure 5 Effect of CRF on actin polymerization in 4T1 cells. 4T1
cells were cultured on coverglass and stimulated with CRF for 2 or
4 h. After fixation, cells were permeabilized and stained for F-actin
with rhodamine-conjugated phalloidin, as described in Materials and
methods. CRF treatment resulted in a more intense actin staining
compared to untreated control, especially after 4 h (A). Moreover,
CRF treated 4T1 cells showed more pronounced actin stress fibers
compared to untreated control (indicated by the arrow). Pictures are
representatives of two independent experiments.
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and b-catenin expression at protein levels. SMAD2 and
b-catenin are two major transcription factors involved
i nm e t a s t a s i s .S M A D 2 ,t o g e t h e rw i t hS M A D 3 ,i sa s s o -
ciated with the TGF-b receptor. When TGF-b binds to
its receptor, SMAD2 and SMAD3 are phosphorylated
and form a complex with SMAD4 that translocates to
the nucleus. In the nucleus, an activated SMAD com-
plex is formed which regulates gene expression and ulti-
mately cell growth [28]. Regarding b-catenin, apart from
being a cell-cell adhesion protein, is also an important
signal transduction molecule in the Wnt signaling path-
way [43]. Induction of Wnt signaling, mostly by affect-
ing b-catenin, has been described as a hallmark of
colon, breast, prostate and ovarian cancer [29]. Interest-
ingly, recent evidence described a link between the
TGF-b and the Wnt-signaling pathways, since receptor-
activated SMAD2 synergistically enhances the Wnt/b-
catenin pathway in epithelial cancer cells [44]. Thus, the
potential effect of CRF on SMAD2 and b-catenin, and
subsequently TGF-b and Wnt signaling, may confer a
novel mechanism for crosstalk between cancer cells and
stress neuropeptides.
Moreover, it has been reported that TGF-b promotes
cell motility and invasiveness in epithelial cancer cells.
In addition, b-catenin is also involved in cytoskeletal
changes characterized by actin polymerization, cell
adhesion and motility [30]. Therefore, we analyzed the
effect of CRF on actin polymerization in 4T1 cells. Our
results showed higher levels of polymerized actin as well
as an increase of actin stress fibers. This suggests that
CRF could promote changes in cytoskeletal structures
that allow cells to migrate and metastasize [45].
The results of the present and our earlier study [18] sug-
gest distinct effects of CRF on breast cancer cells. Several
reports have indicated either tumor promoting or tumor-
inhibitory effects of neuropeptides. Oxytocin has been
shown to suppress proliferation while ghrelin promotes
Figure 6 CRF promotes migration of 4T1 cells and expression of Cox-2. A. 4T1 cells were stimulated with 10
-8M CRF or vehicle (control) in
the presence or absence of Antalarmin and photographed at 0, 6, 12 and 24 hours after disruption of a small area of the cell layer. The
remigration of the cells was quantified by measuring the distance at 3 at least different points of the gap of each image with the program
Image J, and expressing the distance % of the average of the distance initially formed by the disruption (time 0). Results represent the average
of three independent experiments. ++p < 0,01, +++p < 0.001 compared to control cells at the same time point; **p < 0,01; ***p < 0,001
compared to CRF-treated cells at the same time point. B. Expression of Cox-2 was measured in 4T1 stimulated cells by RT-PCR (upper panel) and
real-time RT-PCR. Results represent the average of 3 independent experiments; ***p < 0,001 compared to control cells.
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the effect of grelin on the phenotype depends on the
expression of Estrogen Receptor [47,48]. In our case both
MCF7 and 4T1 are ER+ cell lines suggesting that the dis-
crepancy of the effects does not depend on ER but on
other genetic differences.
Considering the results obtained in vitro, and our earlier
studies in the human breast cancer cell line MCF7 [18],
we used an in vivo model of breast cancer in which
we exposed mice to chronic stress (see Materials and
methods). Antalarmin was administered intraperitoneally
and did not affect chronic stress-induced corticosterone
levels ([27] and present report) but was able to inhibit its
action on tumor cells. Indeed, earlier studies showed that
intraperitoneal administration of antalarmin inhibited the
proinflammatory role of CRF in toxin A-induced intestinal
secretion and inflammation [49] or in the adjuvant
induced arthritis model with Lewis rats [50]. Furthermore,
inhibition of peripheral CRF with i.p. administration of
antalarmin resulted in an increased survival after LPS-
induced endotoxic shock, without affecting the production
of corticosterone [34]. Accordingly, our results showed
that administration of antalarmin intraperitoneally did not
affect the elevation of corticosterone following stress expo-
sure. Once confirmed that in our system the HPA axis was
not affected, we analyzed the effects of peripheral CRF
inhibition on tumor growth. We observed that i.p. admin-
istration of antalarmin in stressed animals resulted in sig-
nificant reduction of tumor burden, which suggests that
peripheral CRF promoted the growth or tumor cells also
in vivo. Moreover, we quantitatively evaluated the extent
of neoangiogenesis in the 4T1 tumors, as an essential pro-
cess for the tumor growth and metastasis. Histological
analysis did not reveal any other changes in the tumors,
such as apoptotic/necrotic lesions. Our experiments
showed that treatment of mice exposed to stress with
antalarmin resulted in reduced angiogenesis compared to
stressed mice injected with vehicle. This suggests that per-
ipheral CRF significantly contributes to neoangiogenesis
observed after stress. Moreover, our results illustrated that
this effect of peripheral CRF is exerted via CRF receptor 1,
s i n c ei tw a si n h i b i t e db yt h es e l e c t i v eC R F 1 antagonist
antalarmin. Interestingly, previous reports have shown a
suppressive effect of Urocortin2 on tumor vascularization
via CRF receptor 2 [51,52] and depletion of CRF1 in mice
suppresses intestinal angiogenesis while ablation of CRF2
augments it, supporting a role for CRF1 signals in angio-
genesis [35]. Also, peripheral CRF has been shown to
enhance local angiogenesis and vascular permeability in
skin via a CRF receptor-dependent mechanism [10,53].
This indicates that different CRF receptors may have dif-
ferent effects on neoangiogenesis. Expression of Cox-2
and VEGF have been associated with neoangiogenesis. In
the case of 4T1 cells CRF induced Cox-2 but not VEGF
expression suggesting that it utilizes a Cox2-dependent,
VEGF-independent mechanism to promote angiogenesis.
Conclusions
Overall, this is the first report showing that CRF affects
TGFb and WNT signaling pathways, major contributors
Figure 7 Peripheral administration of antalarmin does not affect the HPA axis response. As described in Materials and methods, levels of
corticosterone in serum were determined by RIA in the different groups of mice immediately after the last exposure to stress and on the 4
th
day of the interval that followed the last exposure to stress. Increased levels of corticosterone upon stress were not affected by the peripheral
administration of antalarmin (A). Moreover, increased levels of corticosterone after the last exposure to stress were not affected by antalarmin
either, and confirmed the development of chronic stress (B). Data are expressed as MEAN ± SEM. Five animals per group were used. * p < 0.05,
compared to control not exposed to stress.
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used and the percentage of tumor bearing mice and the extend of neoangiogenesis were determined as described in Materials and methods.
(A) Peripheral administration of antalarmin diminished the stress-induced increase of the percentage of tumor bearing mice. (B) Representative
pictures of the histological analysis. (C) The area of vascularization is increased in animals exposed to stress but this effect is abolished by the
inhibition of peripheral CRF by the ip administration of antalarmin. ** p < 0.01 compared to control without tumor. # p < 0.05 compared to
tumor-bearing mice injected with vehicle. + p < 0.05 compare to tumor-bearing mice exposed to stress and injected with vehicle.
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Page 9 of 13in breast tumor growth. In addition, it is the first report
demonstrating in vivo that peripheral CRF mediates the
effects of stress on breast tumor growth. Hence, this
suggests that inhibition of peripheral CRF may be bene-
ficial for suppressing stress-induced breast tumor
growth.
Experimental Procedures
Cell Culture
The mouse mammary tumor cell line 4T1 was cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) and 1% penicillin/streptomycin (all purchased
from GIBCO, UK) at 37°C in a 5% CO2 humidified
atmosphere. For cell stimulations, 4T1 cells were plated
one day before stimulation at 500.000 or 250.000 cells
per well in 6-well or 24-well plates, respectively. Subse-
quently, medium was refreshed and supplemented with
(or without for controls) synthetic rat/human CRF
(Tocris, Bioscience, UK) at a concentration of 10
-8M.
Reverse transcriptase PCR
Total cellular RNA was isolated using Trizol reagent (Invi-
trogen, UK). cDNA was prepared by reverse transcriptase
PCR (Superscript RT, Invitrogen) and amplified by PCR
using the following primer pairs: CRFR1: fwd 5’-G C C
GCC TAC AAT TAC TTC CA-3’,r e v5 ’-C G GA G T
TTG GTC ATG AGG AT - 3’ and CRFR2: fwd 5’- GGA
GCC CTA GTG GAG AGA CC -3’,r e v5 ’-A G GT G G
TGA TGA GGT TCC AG -3’, VEGF: 5’- GTACCTCCAC-
CATGCCAAGT-3’,5 ’- ACTCCAGGGCTTCATCGTTA
-3’,C o x - 2 :5 ’- GCTTGCATTGATGGTGGCTG-3’,5 ’-
CCAGATGCTATCTTTGGGGAGAC-3’. For each PCR
reaction, 1 μl of cDNA was used together with primers
indicated above, at 45 cycles and an annealing temperature
of 60°C. 10 μl of amplified products were separated on a
1.5% agarose gel and visualized by ethidium bromide
staining, or subjected to real-time PCR using SYBRgeen
method as previously reported [54].
MTT viability assay
To determine the effect of CRF on cell proliferation,
MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide) cell viability assays were performed.
4T1 cells were plated in flat-bottomed 96-well plates at
a 5000 cells/well concentration and allowed to adhere
overnight. The following day the medium was changed
by fresh DMEM supplemented or not with 10
-8 MC R F .
To determine cell growth, after 24 and 48 hours, 50 μg
MTT (Sigma-Aldrich, USA) was added to each well and
the plates were incubated an additional 4 h at 37°C and
5% CO2. After 4 h the supernatant was removed and
the formed crystals were dissolved in 100 μl 0,04N HCL
in isopropanol. The plates were analyzed at 570 nm
with a microplate reader (Bio-Rad, UK). All assays were
performed in quadruplicate and the mean values for
each data point was calculated from the combined data.
Gene expression arrays
Total RNA from 4T1 cells was isolated using Trizol
reagent (Invitrogen), following the manufacturer’s
recommendations. Using the TrueLabeling-AMP™ 2.0
kit, (Superarray Bioscience Corp., Frederick, Md.), the
RNA was reversely transcribed to obtain cDNA and
converted into biotin-labeled cRNA using biotin-16-
UTP (Roche, Mannheim, Germany) by in vitro tran-
scription. cRNA probes were then purified with the
ArrayGrade cRNA cleanup kit (Superarray) and hybri-
dized to the pretreated Oligo GEArray® Mouse Tumor
metastasis microarray (Superarray). Following washing
steps, array spots binding cRNA were detected using
alkaline phosphatase-conjugated streptavidin and CDP-
Star as chemiluminescent substrate. Signal was detected
by exposure to high-performance chemiluminescence
films (Amersham Biosciences, UK). The image data
were transformed into numerical data using GEArray
Expression Analysis Suite software (SuperArray
Bioscience). To normalize the data, background signal
was subtracted and the intensity of all genes was
referred to GAPDH as an endogenous control. Data fil-
tering criteria were as follows: at least one of the spot
intensities to be compared had to be more than twice
the background intensity, and the spot intensity ratios
had to be ± 40% in all set of samples analyzed to con-
sider up or down-regulation. Finally, mean expression of
each gene was transformed into color intensity using
the program TIGRMultiExperiment Viewer V4.5.1.
Western blot analysis
Western blot analysis for the detection of SMAD2 (sc-
6200, Santa Cruz, US) and b-catenin (sc-7199, Santa Cruz)
were performed. After treatment, cells were harvested and
lysed in buffer, containing 1.5 mM Tris (Bio-Rad Labs),
150 mM NaCL, 0.1% SDS, 1% NP-40, 0.02% Sodium
Azide, pH 8, with proteinase inhibitors 4% complete and
1% PMSF (phenylmethylsulfonyl fluoride) (all from Sigma)
as previously described [55]. Cell lysates were sonicated
for 4 seconds and solid cellular debris were removed by
centrifugation at 12.000 rpm for 10 min. Lystates were
stored at -80°C until use. 20 ug of lysate was loaded in a
12% SDS-polyacrylamide gel, transferred to nitrocellulose
membranes and processed according to standard Western
blotting procedures. To normalize for protein content the
blots were stripped in buffer containing 62.5 mM Tris-
HCl, pH 6.7, 2% SDS, 100 mM b-mercaptoethanol and
stained with anti-tubulin antibody (T4026, Sigma).
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vs tubulin. NIH image software (ImageJ) was used to
quantify the intensity of each band.
Immunofluorescence
4T1 cells were cultured at a concentration of 30.000
cells per well in 8-well chamber slides. After 24 h fresh
medium supplemented with CRF at a concentration of
2×1 0
-8M was added. After 2 or 4 h cells were fixed
with 3.7% formaldehyde in PBS for 10 min, permeabi-
lized with acetone for 4 min, washed with PBS and
blocked with 1.5% FCS in PBS for 15 min. The chamber
slides were subsequently incubated with rhodamine-
phalloidin (Sigma) at a 1:100 dilution in 1.5% FCS in
PBS, for 30 min at dark. Cells probed with rhodamine-
phalloidin were washed with PBS and immediately
mounted and stored at -20°C until observation with
confocal laser scanning microscopy.
Wound healing assay
Cells were cultured in 60 mm plates until they fromed a
monolayer. A small area was then disrupted and a
group of cells was destroyed or displaced by scratching
a line through the layer with a tip [18]. The culture
medium was replaced with serum free medium and cells
received the stimulus (CRF and/or Antalarmin). The
open gap was then inspected microscopically (Leica,
Germany) over time as the cells moved in and filled the
damaged area. Images were captured at the beginning
and at regular time points during cell migration and the
cell migration was quantified by measuring the distance
with the program Image J http://rsbweb.nih.gov/ij/
between two certain points on either side of the gap.
For proper statistical evaluation, at least three measure-
ments at different points were performed at each image.
Transfections and luciferase assay
4T1 cells were transfected with a pGL3 plasmid contain-
ing a WNT-reporter sequence harbouring 3 TCF bind-
ing sites linked to the luciferase by lipofectamine™ 2000
(Invitrogen), according to the manufacturer’si n s t r u c -
tions. In parallel experiments, the same plasmid was
used that carries a point mutation in the TCF binding
site. In brief, one day before transfection, cells were pla-
ted at 1,5 × 10
5 cells/well in 500 μl medium in 24-well
plates. Plasmid DNA and lipofectamine both diluted in
Opti-MEM I reduced serumm e d i u mw i t h o u ts e r u m
(Invitrogen), were mixed at a 1:2 ratio (1 μgD N A :2μl
lipofectamine/well) and incubated for 20 min at room
temperature. After 20 min incubation, 100 μlo fp l a s -
mid/liposome complex was added to each well, and cells
were incubated for 24 hours at 37°C and 5% CO2.M e d -
ium was refreshed after 4 hours with normal culture
medium containing 10
-8 M CRF, cells were lysed after
18 hours. Luciferase assay was performed with the Dual-
Luciferase® Reporter Assay System (Promega), according
to the manufacturer’s manual. Each transfection was
performed in triplicate to allow statistical evaluation and
control for possible variations in transfection efficiency.
RIA
Corticosterone was measured by RIA in serum collected
at the indicated time points. Five animals per group
were used. Sera were frozen at -70°C and analyzed as
recommended by the manufacturer (ICN, USA).
Animals
Six to eight weeks old Balb/c female mice were pur-
chased from the Hellenic Pasteur Institute (Athens,
Greece). All procedures described below were approved
by the Animal Care Committee of the University of
Crete School of Medicine, Heraklio, Crete, Greece and
from the Veterinary Department of the Heraklion Pre-
fecture, Heraklio, Crete, Greece.
In vivo model of breast tumor and restraint stress
One million 4T1 cells were implanted in the mammary
fat pad of Balb/c mice and three different groups were
created. One group was injected intraperitoneally with
20 mg/kg antalarmin everyday. A second group was
exposed to restraint stress for 3 hours for 4 consecutive
days following a 5 day interval. The third group was
exposed to the same type of restraint stress and in addi-
tion received 20 mg/kg antalarmin daily, dissolved in
cremaphor (Sigma). Control group was subjected to the
same surgical procedure, without the implantation of
tumor cells.
We used antalarmin for inhibition of CRF receptors
since CRF functions primarily via CRF1,t h et a r g e to f
antalarmin. Mice that did not receive antalarmin
received an injection of vehicle at the same time points.
At different time points (either before or immediately
after the restraint period) samples were collected by the
retroorbital route to measure corticosterone in the
plasma. The experiment was terminated 6 weeks later.
At the end of the experiment mammary glands were
visualized on the animal to determine the extent of
neoangiogenesis and samples were collected from the
different groups and histological analysis was performed.
Angiogenesis determination
To quantitatively measure angiogenesis an in-house
developed method was used. Briefly, this method utilized
the contrast of autofluorescence between the mammary
tissue and the blood vessels. Blood vessels greatly absorb
visible light, while mammary gland and mammary
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Page 11 of 13tumors are strongly autofluorescent. User-friendly soft-
ware developed in-house was used in order to quantify
the area of vascularization vs total area.
Histological analysis
Mammary glands samples were collected as specified
above and fixed in formalin. Sections were stained with
Haematoxylin-Eosin using standard techniques. Presence
of tumors was determined by the same pathologist
blinded to the treatment conditions. Percentage of
tumor bearing mice was calculated per each group.
Statistical analysis
Comparison between groups was made using the Stu-
dent’s t-test and ANOVA test, and p < 0.05 was consid-
ered significant.
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